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Hereditary angioedema (HAE) is a rare, but potentially life-
threatening disease characterised by attacks of swellings. 
It is caused by a lack of functioning C1 esterase inhibitor 
(C1INH). The oedema is usually located to the face, extre-
mities or abdominal mucosa, but may involve the larynx. 
Although rare, the laryngeal attacks are particularly dreaded 
due to the risk of asphyxiation. It is known that HAE can 
have substantial impact on health-related quality of life 
(HRQoL) (1, 2). Today, Danish HAE patients have access 
to several modalities of treatment including intravenously 
administered C1INH concentrate (3). Patients are offered 
training in self-injection if they suffer from frequent and/
or severe attacks. The aim of this study was to investigate 
HRQoL in Danish HAE patients. 
METHODS 
The study was carried out in 2009 at the Danish HAE Compre-
hensive Care Centre, Odense University Hospital. Twenty-seven 
Danish HAE patients filled out The Short Form (36) Health Sur-
vey, version 2 (SF-36v2) and a clinical questionnaire. Patients 
were asked about number and locations of attacks within the 
last 6 months, age of onset, types of treatment and ability to do 
self-injection. Danish population norms for SF-36v2 were not 
available, it was recommended by the producers to compare to the 
US population norms (4). To examine if there was any correlation 
between disease severity and score in SF-36v2, a clinical severity 
score recently developed by Bygum et al. (5) was used. Patients 
were divided into 3 groups based on disease severity, and for 
each group median scores in SF-36v2 were calculated. We also 
examined whether scores in SF-36v2 were related to self-injection 
with C1INH concentrate by calculating median scores for the 
self-injecting and non-self-injecting subgroup, respectively.
RESULTS
Fig. 1 outlines the SF-36v2 mean score reported for 8 spe-
cific dimensions. In all dimensions but one, HAE patients 
rate equally to or higher than the general population. The 
relation between disease severity and median scores in SF-
36v2 is illustrated with a box and whiskers plot (Fig. 2). In 
all dimensions there is no statistically significant difference 
in median score between the 3 severity groups (p > 0.05 in 
Kruskall-Wallis test). In the study, 25 patients had C1INH 
concentrate at home and 11 were able to do self-injection. 
In the dimension General health the self-injecting subgroup 
scored lower than the non-self-injecting subgroup (median 
58 [39.3–67.8] versus median 77 [55.8–92.8], p = 0.049 in 
Mann Whitney U rank-sum test). Otherwise there was no 
difference between the 2 groups. Nor did we find any general 
correlation between scores in SF-36v2 and the number of 
attacks within the last 6 months (data not shown).
DISCUSSION 
It is noteworthy in our study that mean scores in SF-36v2 
generally correspond well to the population norms. How-
ever, it has to be taken into consideration that the applied 
population norms were calculated in 1998 in the US. Also, 
the presented data are based on only 27 subjects and there-
fore have considerable statistical limitations. Still, such a 
cohort is sizeable for this rare condition. 
Recently, a Brazilian study on HAE also based on SF-
36v2 showed a significantly lower mean score in all dimen-
sions (6). A possible explanation is the difference in treat-
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Fig. 2. Median scores in the 8 dimensions of SF-36v2 grouped by severity 
score. Group 1 has 4–6 points on the severity score, group 2 has 7–8 points 
and group 3 has 9–10 point. Single points are outliers. For abbreviations 
see Fig. 1.
Fig. 1. Mean scores in SF-36v2 for Danish hereditary angioedema (HAE) 
patients vs. US population norms. PF: physical functioning; SF: social 
functioning; RP: role-physical; RE: role-emotional; MH: mental health; 
VT: vitality; BP: bodily pain; GH: general health.
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Mean scores for HAE patients:
PF 88.7 (± 20.8), SF 92.9 (± 12.7),
RP 85.6 (± 23.4), RE 89.4 (± 24.2),
MH 81.9 (± 14.6), VT 66.3 (± 21.8),
BP 78.6 (± 24.9), GH 62.8 (± 24.2).
US population norms:
PF 83.3 (± 23.8), SF 84.3 (± 22.9),
RP 82.5 (± 25.5), RE 87.4 (± 21.4),
MH 75.0 (± 17.8), VT 58.3 (± 20.0),
BP 71.3 (± 23.7), GH 70.8 (± 21.0)
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ment options and health care systems between the countries. 
Danish patients are followed regularly at a specialist centre 
and have access to necessary medication and around the 
clock counselling. Treatment with C1INH concentrate was 
not approved in Brazil at the time of the study by Gomide 
et al. (6) and patients answering the questionnaire only 
had access to treatment with tranexamic acid or attenuated 
androgen (confirmed by correspondence with the authors). 
Both treatments are also used in Denmark, but to a lesser 
extent since newer treatments have better efficacy and fewer 
side effects. Twenty-five of the Danish patients had C1INH 
concentrate at home, and it has previously been shown that 
administration of C1INH concentrate is associated with QoL 
benefits (7–9). In our study we found no general difference 
in SF-36v2 scores between the self-injecting and non self-
injecting patients. Only in the dimension General health 
there was a significantly lower score in the self-injecting 
subgroup. One reason for this could be that although home 
treatment has many benefits it is also a frequent reminder 
to the patients of their chronic disease. It should also be 
taken into consideration that training in self-injection is 
typically offered to patients with more frequent and/or 
severe attacks. This might influence their answers in the 
SF-36v2 questionnaire.
Recently, Caballero et al. (2) found that attack severity 
and frequency were significant predictors of HAE-related 
anxiety, whereas our study does not report any significant 
correlation between disease severity and HRQoL. Only 
a few HAE severity score systems exist and there does 
not seem to be consensus on which provides the best data 
(10, 11). It has previously been shown that early onset 
of symptoms is associated with a more severe cause of 
disease (2, 12). In our experience, age at onset combined 
with information on which areas of the body have been 
affected provide useful information about general disease 
severity, whereas need for long-term prophylaxis indicates 
a certain frequency and/or severity of attacks. The score 
developed by Bygum et al. (5), was initially developed 
to represent a cumulated disease score and not an actual 
activity score. But even when looking at current disease 
activity represented by number of attacks within the last 
6 months, there is no general correlation to scores in SF-
36v2. It seems that, as in many other diseases, the burden of 
illness in HAE is not only determined by disease severity. 
At least from this study we see that HAE patients with 
access to new therapies and regular visits at a specialist 
centre have SF-36v2 scores comparable to the general 
population. This emphasises the need for tailored patient 
care programs and a regular monitoring of QoL. Indeed, 
international HAE guidelines recommend that HRQoL 
should be measured annually (13). The SF-36v2 can be a 
useful tool for evaluating HRQoL for patients with various 
types of conditions, including HAE. However, it does not 
address the special characteristics and challenges of the 
disease. This could explain why we do not retrieve any 
clear correlation between disease severity and HRQoL, 
as seen in other studies. Thus, there is a need for disease-
specific tools to fully cover all QoL-related areas affected 
by HAE. Weller et al. (14) recently published a QoL ques-
tionnaire for recurrent angioedema which includes but is 
not specific for HAE. An international HAE-specific QoL 
questionnaire is currently being developed in Spain, and 
the Danish HAE Comprehensive Care Centre has been 
participating in its validation and translation (15).
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